Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.
| Status: | Withdrawn |
|---|---|
| Conditions: | Hepatitis, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/10/2017 |
| Start Date: | December 2011 |
| End Date: | January 2016 |
The purpose of the study is to determine differences in levels of serum chemokines from
patients undergoing treatment with Boceprevir. The aim is to determine if non-responders have
significantly different levels of chemokines than responders.
patients undergoing treatment with Boceprevir. The aim is to determine if non-responders have
significantly different levels of chemokines than responders.
Patients undergoing standard of care at the UNC Liver Center are consented for collection of
an additional serum sample under the UNC Liver Center serum and tissue bank study. These
samples will be used to analyze differences in serum chemokines across responders and
non-responders.
an additional serum sample under the UNC Liver Center serum and tissue bank study. These
samples will be used to analyze differences in serum chemokines across responders and
non-responders.
Inclusion Criteria:
- All adult patients (age 18 or older) treated with an antiviral Hepatitis C treatment
regimen that includes Boceprevir.
Exclusion Criteria:
- Inability to provide informed consent for a serum sample enrolled in the University of
North Carolina Liver Center serum bank.
- No pre and post serum sample available within 6 months of the treatment period.
We found this trial at
1
site
Click here to add this to my saved trials
